Previous Article | Next Article 
Journal of Clinical Microbiology, July 2001, p. 2655-2659, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2655-2659.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Use of a Reverse Dot Blot Procedure To Identify the Presence
of Multiple Serovars in Chlamydia trachomatis
Urogenital Infection
Diane R.
Stothard*
Department of Medicine, Division of
Infectious Diseases, Indiana University School of Medicine,
Indianapolis, Indiana 46202
Received 18 September 2000/Returned for modification 22 January
2001/Accepted 23 April 2001
 |
ABSTRACT |
Epidemiologic research requires identification of Chlamydia
trachomatis serovars and detection of mixed infection.
Antibody-based serotyping is unworkable when specimens are urine or
vaginal swabs. We developed a reverse dot blot (RDB) to screen for
multiple serotypes in these specimens. RDB yielded the predicted
results on all artificially mixed samples and on seven of eight
clinically mixed samples.
 |
TEXT |
There are ~17 serovars of
Chlamydia trachomatis which cause either ocular
or sexually transmitted infection (25-27). The immunodominant major outer membrane protein (MOMP), encoded by the
omp1 gene (1, 5-7, 15, 25, 26, 29, 30), is the
most variable genetic marker known for chlamydiae, making it a useful
epidemiologic tool.
Serotyping of chlamydia is unnecessary for clinical diagnosis. However,
unequivocal strain identification for clinical samples is required in
epidemiologic research. While most specimens from chlamydia-infected
individuals contain only one serovar, 2 to 15% of infections contain
two or more (2-4, 8, 16, 28).
Antibody-based procedures such as fluorescent antibody (FA) staining,
enzyme immunoassay, or radioimmunoassay are commonly used for both
serotyping and detection of multiple serotypes but require cell culture
of chlamydiae. DNA sequencing does not require cell culture, provides
serovar identification, and has detected multiple serovars (3, 4,
8). However, sequencing of a mixed sample yields ambiguous
results at best because the serovars in the mixture cannot be resolved
unless the omp1 PCR products are cloned and multiple clones
are then sequenced.
We are studying chlamydia transmission between sexual contacts and
reinfection patterns in a large group of adolescent women where
unambiguous identification of serotypes and detection of mixed
infection are essential. We use PCR tests to detect chlamydiae from
self-administered vaginal swabs and/or urine, and we use sequencing to
determine the serovar. Since sequencing does not reliably detect mixed
infections, we developed a reverse dot blot (RDB) procedure as a
screen. We first PCR amplify the omp1 gene and then
hybridize labeled amplicons to serotype-specific omp1 oligonucleotides. RDB can detect multiple serovars in a specimen and
does not require chlamydia culture or cloning.
Chlamydial elementary bodies (EB) were prepared (17) from
strains A/571-B/OT, B/TW-5/OT, Ba/Ap-2/OT, C/TW- 3/OT,
D/UW-3/Cx, E/UW-5/Cx, F/UW-6/Ur, G/UW-57/Cx, H/UW-4/Cx,
I/UW-12/Ur, J/UW-36/Cx, and K/UW-53/Cx. Eight archived clinical
specimens were used: 52, 61A, 154, 229, 814, 831, 900, and 910 (see
Table 2).
DNA was extracted and omp1 amplified by PCR from clinical
and laboratory samples as previously described (23, 24).
For laboratory-created mixtures, DNAs (1 to 100 ng) from two different serovars were mixed together in the PCR at ratios ranging from 1:1 to
1:100. PCR products were purified using the QIAquick PCR purification
kit (QIAgen), quantified, and labeled with digoxigenin (DIG) using the
DIG Chem-link kit (Roche Molecular Biochemicals, Indianapolis, Ind.)
according to instructions. The PCR probes were either used immediately
or stored at
20°C.
Twelve oligonucleotides were designed based on published
omp1 sequences (1, 9-12, 19-23, 31) (Amitof
Biotech, Alston, Mass.) and made to hybridized specifically to serovars
A to K (Table 1). The C-type
oligonucleotide based on the published C/TW-3/OT sequence
(22) failed to hybridize and was redesigned based on new
sequencing of C/TW-3/OT (GenBank accession no. AF352789). A
positive-control oligonucleotide was designed to hybridize with all
serovars (Table 1). Poly(dT) tails were added to the 3' ends of
oligonucleotides via a terminal transferase reaction to facilitate binding to membranes. Tailed oligonucleotides were either used immediately or stored at
20°C.
All protocols for hybridization and detection are found in the
DIG System User's Guide for Filter Hybridization (Roche).
Positively charged nylon membranes (Roche) were cut into 2-by
7.5-cm strips. Three picomoles of each poly(dT)-tailed oligonucleotide
was spotted onto the strips at 0.5-cm intervals. The spots were air
dried and then UV cross-linked to strips using the UV Stratalinker
(Stratagene). Strips were prehybridized at 45°C for 30 min and then
hybridized at 42°C for 90 min. After posthybridization washes,
detection was done using an anti-DIG-alkaline phosphatase conjugate
and nitroblue tetrazolium
(NBT)-5-bromo-4-chloro-3-indolylphosphate (BCIP) color substrate. Development was carried out in the dark for 1 to 2 h. Strips were air dried and photographed.
Specificity.
Oligonucleotides hybridized specifically with
their corresponding omp1 PCR products (Fig.
1A). Cross-hybridization was found between J and Ja oligonucleotides and the J probe (FA staining does not
distinguish J from Ja), although the spot created by the exact
match is darker (Fig 1C; compare 154, which contains J, and 910, which
contains Ja). Cross-hybridization was seen between the J
oligonucleotide and the C probe. Cross-hybridization can also be found
in FA staining between C- and J-specific monoclonal antibodies
(12, 18). However, even in areas where trachoma is
endemic, serovar C is rarely found in urogenital infections (3,
4). Therefore, the importance of this cross-reaction is
negligible.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 1.
RDB results on laboratory and clinical samples.
Serotype-specific oligonucleotides are bound in the order A to K, from
left to right, on nylon strips. PCR products labeled with DIG are
hybridized to the strips. Positive hybridization is visualized as a
dark-purple spot on the membrane. (A) MOMP PCR products generated from
purified EB are hybridized to strips containing all 12 serotype-specific oligonucleotides and the positive-control
oligonucleotide. (B) Laboratory mixed samples were generated by mixing
known quantities of DNAs purified from EB of serotypes B, E, and F at
different ratios. Positive hybridization results are visualized as
dark-purple spots on the membrane. The strips contain all 12 serotype-specific oligonucleotides and the positive-control
oligonucleotide as in panel A. (C) RDB hybridization results from
clinical specimens containing multiple serovars of chlamydia. PCR
products were generated from clinical specimens after they had been
expanded in cell culture and prior to their expansion in cell culture
(results identical to those shown here).
|
|
Mixed-serovar laboratory samples.
DNAs from serovars B and E
in one set and from serovars F and I in another were mixed at different
ratios. Spots for both serovars were visible (Fig. 1B). DNAs from
serovars E and F were mixed in different ratios. For all ratios tested,
we were able to visualize both E and F. In the 1:100-ng ratio mixture,
the 1-ng spot is light but still visible (Fig. 1B).
Mixed-serovar clinical specimens.
Eight archived samples
known to contain more than one serovar of chlamydia by
FA staining were evaluated. The number of inclusion-forming units (IFU) for each specimen had been quantified (Table
2), except for isolates 52 and 229. FA
and RDB results were identical except for isolates 52 and 910 (Fig.
1C). FA staining detected serovars D and E in specimen 52, while RDB
detected only serovar E. In specimen 910, FA staining detected serovars
E and J or Ja, while RDB detected E, Ja, and a faint spot corresponding
to serovar Ia. Specimens 52 and 910 were retyped by FA staining. Upon
retyping, specimen 52 contained only serovar E chlamydiae. The isolate
had been passaged in culture three times since the initial typing in
1996.
It is possible that during expansion of specimen 52 in culture, E cells
outgrew D cells. For specimen 910, it is possible
that the additional
Ia spot detected by RDB was a contaminant
in the expanded culture or
PCR. Nested PCR (
23) was done on
an aliquot of the
original clinical specimen (stored in transport
medium at

70°C).
Results of RDB on the original specimen were
identical to results for
the expanded isolates (data not
shown).
The eight clinical mixed samples were sequenced using MOMP-87,
which extends through variable and constant regions of
omp1 (
23,
24) (Fig.
2 and Table
2). Either one discernible sequence
or an
ambiguous mixture was obtained. Thus, sequencing did not
dependably
determine (i) that a mixture was present in the sample
or (ii) the
identity of the serotypes in the mixture.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 2.
Automated DNA nucleotide sequencing of the
omp1 genes of clinical specimens containing multiple
serovars. The omp1 gene was amplified from all eight
clinical isolates with mixed serovars and sequenced with the MOMP-87
primer (23), which begins at approximately base 87 in the
omp1 gene and extends though conserved regions (CS) 1, 2, and 3 and variable regions (VS) 1 and 2 of the omp1 gene.
Sequencing electropherogram results are from specimen 154, which
contains serovars E and J in a 1:5 ratio (A), and from specimen 900, which contains serovars E and Ia in a 2:1 ratio (B) in both
examples are, on the top row, bases ~197 to 229 in CS1 and, on the
bottom row, bases ~318 to 345, near the end of VS1 of the
omp1 gene. Evidence of a mixture can be seen in specimen 154 but not in specimen 900.
|
|
The
omp1 gene of
C. trachomatis has been a useful
marker in epidemiologic studies (
3,
4,
28) and for the
study of
transmission patterns (
13,
14). We are examining
the transmission
of discrete strains within two study populations and
use the
omp1 gene as a molecular marker. Because these are
large studies, the
clinical specimens are self-collected vaginal swabs
and urine,
with primary chlamydia detection by diagnostic PCR. Culture
is
not performed, making screening for mixed infections by FA staining
impossible. DNA sequencing does not reliably detect mixed samples
(Fig.
2 and Table
2), and even if mixtures are detected, serovar
determination requires cloning of amplicons followed by sequencing
of
multiple clones. As an example, serovars E and Ja are present
at a
ratio of 1:10 in specimen 910. Using the binomial equation,
if we
sequence 20 clones, there is only a 70% chance of finding
one serovar
E
clone.
The eight clinical specimens tested were the only ones in our archives
dating back to 1986 that contained more than one serovar
detected by FA
staining and for which both the original specimen
and the expanded
isolate could be found. Upon retyping for this
study, only serovar E
could be found in specimen 52. Thus, RDB
results agreed with FA results
in seven of eight mixed-serovar
specimens. While RDB results on these
samples were satisfactory,
further testing of this procedure is
recommended.
For large epidemiologic studies, when chlamydia culture is not an
option, RDB is a simple and sensitive technique for screening
and
identification of multiple serovars of chlamydia in a clinical
specimen. Although we use
omp1 sequencing for primary strain
identification,
RDB could also be used to identify the serovar of
chlamydia present
in a clinical sample if serovar-specific antibodies
are not available
or if chlamydia culture is not done. In addition, RDB
can be modified
for detection of other organisms isolated from
human infections,
or in a multiplex format to detect several different
organisms,
such as
C. trachomatis and
Neisseria
gonorrhoeae, in a single
clinical
specimen.
 |
ACKNOWLEDGMENTS |
I thank Rebecca Gast, Woods Hole Oceanographic Institute,
for technical advice, and Greg Toth for superb technical assistance.
This work was supported by NIH grant U19AI43924, Mid-America Adolescent
Sexually Transmitted Diseases Cooperative Research Center (project 2),
awarded by the National Institute of Allergy and Infectious Diseases.
 |
FOOTNOTES |
*
Mailing address: Department of Medicine, Division of
Infectious Diseases, Indiana University School of Medicine, 435 Emerson Hall, 545 Barnhill Dr., Indianapolis, IN 46202. Phone: (317) 274-7673. Fax: (317) 275-1587. E-mail: dstothar{at}iupui.edu.
 |
REFERENCES |
| 1.
|
Baehr, W.,
Y.-X. Zhang,
T. Joseph,
H. Su,
F. E. Nano,
K. D. E. Everett, and H. D. Caldwell.
1988.
Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes.
Proc. Natl. Acad. Sci. USA
85:4000-4004[Abstract/Free Full Text].
|
| 2.
|
Batteiger, B. E,
W. Lennington,
W. J. Newhall,
B. P. Katz,
H. T. Morrison, and R. B. Jones.
1989.
Correlation of infecting serovar and local inflammation in genital chlamydial infections.
J. Infect. Dis.
160:332-336[Medline].
|
| 3.
|
Brunham, R. C.,
J. Kimani,
J. Bwayo,
G. Maitha,
I. Maclean,
C. Yang,
C. Shen,
S. Roman,
N. J. D. Nagelkerke,
M. Cheang, and F. A. Plummer.
1996.
The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group.
J. Infect. Dis.
173:950-956[Medline].
|
| 4.
|
Brunham, R. C.,
C. Yang,
I. Maclean,
J. Kimani,
G. Maitha, and F. A. Plummer.
1994.
Chlamydia trachomatis from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp1) gene.
J. Clin. Investig.
94:458-463.
|
| 5.
|
Caldwell, H. D.,
J. Kromhout, and J. Schachter.
1981.
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.
Infect. Immun.
31:1161-1176[Abstract/Free Full Text].
|
| 6.
|
Caldwell, H. D., and R. C. Judd.
1982.
Structural analysis of chlamydial major outer membrane proteins.
Infect. Immun.
38:960-968[Abstract/Free Full Text].
|
| 7.
|
Caldwell, H. D., and J. Schachter.
1982.
Antigenic analysis of the major outer membrane protein of Chlamydia spp.
Infect. Immun.
35:1024-1031[Abstract/Free Full Text].
|
| 8.
|
Dean, D.,
E. Oudens,
G. Bolan,
N. Padian, and J. Schachter.
1995.
Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco.
J. Infect. Dis.
172:1013-1022[Medline].
|
| 9.
|
Farencena, A.,
M. Comanducci,
M. Donati,
G. Ratti, and R. Cevenini.
1997.
Characterization of a new isolate of Chlamydia trachomatis which lacks the common plasmid and has properties of biovar trachoma.
Infect. Immun.
65:2965-2969[Abstract].
|
| 10.
|
Hamilton, P. T., and D. P. Malinowski.
1989.
Nucleotide sequence of the major outer membrane protein gene from Chlamydia trachomatis serovar H.
Nucleic Acids Res.
17:8366[Free Full Text].
|
| 11.
|
Hayes, L. J., and I. N. Clark.
1990.
Nucleotide sequence of the major outer membrane protein gene of Chlamydia trachomatis strain A/SA1/OT.
Nucleic Acids Res.
18:6136[Free Full Text].
|
| 12.
|
Hayes, L. J.,
M. A. Pickett,
J. W. Conlan,
S. Ferris,
J. S. Everson,
M. E. Ward, and I. N. Clark.
1990.
The major outer membrane proteins of Chlamydia trachomatis serovars A and B: intra-serovar amino acid changes do not alter specificities of serovar- and C subspecies-reactive antibody-binding domains.
J. Gen. Microbiol.
136:1559-1566[Abstract/Free Full Text].
|
| 13.
|
Hayes, L. J.,
R. L. Bailey,
D. C. W. Mabey,
I. N. Clarke,
M. A. Picket,
P. J. Watt, and M. E. Ward.
1992.
Genotyping of Chlamydia trachomatis from a trachoma-endemic village in The Gambia by a nested polymerase chain reaction: identification of strain variants.
J. Infect. Dis.
166:1173-1177[Medline].
|
| 14.
|
Hayes, L. J.,
S. Pecharatana,
R. L. Bailey,
T. J. Hampton,
M. A. Picket,
D. C. W. Mabey,
P. J. Watt, and M. E. Ward.
1995.
Extent and kinetics of genetic change in the omp1 gene of Chlamydia trachomatis in two villages with endemic trachoma.
J. Infect. Dis.
172:268-272[Medline].
|
| 15.
|
Hatch, T. P.,
D. W. Vance, and E. Al-Hossainy.
1981.
Identification of a major envelope protein in Chlamydia spp.
J. Bacteriol.
146:426-429[Abstract/Free Full Text].
|
| 16.
|
Morre, S. A,
L. Rozendaal,
I. G. M. van Valkengoed,
A. J. P. Boeke,
P. C. van Voorst Vader,
J. Schirm,
S. de Blok,
J. A. R. van den Hoek,
G. J. J. van Doornum,
C. J. L. M. Miejer, and A. J. C. van den Brule.
2000.
Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations?
J. Clin. Microbiol.
38:2292-2296[Abstract/Free Full Text].
|
| 17.
|
Newhall, W. J.,
B. Batteiger, and R. B. Jones.
1982.
Analysis of the human serologic response to proteins of Chlamydia trachomatis.
Infect. Immun.
38:1181-1189[Abstract/Free Full Text].
|
| 18.
|
Persson, K., and S. Osser.
1989.
Serovars of Chlamydia trachomatis causing post-abortion salpingitis.
Eur. J. Clin. Microbiol. Infect. Dis.
8:795-798[CrossRef][Medline].
|
| 19.
|
Peterson, E. M.,
B. A. Markoff, and L. M. de la Maza.
1990.
The major outer membrane protein nucleotide sequence of Chlamydia trachomatis, serovar E.
Nucleic Acids Res.
18:3414[Free Full Text].
|
| 20.
|
Sayada, C.,
E. Denamur, and J. Elion.
1992.
Complete sequence of the major outer membrane protein-encoding gene of Chlamydia trachomatis serovar Da*.
Gene
120:129-130[CrossRef][Medline].
|
| 21.
|
Sayada, C.,
E. Vretou,
J. Orfila,
J. Elion, and E. Denamur.
1995.
Heterogeneity within the first constant segment of the major outer membrane protein gene in Chlamydia trachomatis serovar D/Da distinguishes two lineages.
C. R. Acad. Sci.
318:943-949.
|
| 22.
|
Stephens, R. S.,
R. Sanchez-Pescador,
E. A. Wagar,
C. Inouye, and M. S. Urdea.
1987.
Diversity of Chlamydia trachomatis major outer membrane protein genes.
J. Bacteriol.
169:3879-3885[Abstract/Free Full Text].
|
| 23.
|
Stothard, D. R.,
G. Boguslawski, and R. B. Jones.
1998.
Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein (MOMP) and examination of potential pathogenic determinants.
Infect. Immun.
66:3618-3625[Abstract/Free Full Text].
|
| 24.
|
Stothard, D. R.,
B. Van Der Pol,
N. J. Smith, and R. B. Jones.
1998.
Effect of serial passage in tissue culture on sequence of omp1 from Chlamydia trachomatis clinical isolates.
J. Clin. Microbiol.
36:3686-3688[Abstract/Free Full Text].
|
| 25.
|
Wang, S. P.,
J. T. Grayston,
E. R. Alexander, and K. K. Holmes.
1975.
Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody.
J. Clin. Microbiol.
1:250-255[Abstract/Free Full Text].
|
| 26.
|
Wang, S. P,
C.-C. Kuo,
R. C. Barnes,
R. S. Stephens, and J. T. Grayston.
1985.
Immunotyping of Chlamydia trachomatis with monoclonal antibodies.
J. Infect. Dis.
152:791-800[Medline].
|
| 27.
|
Wang, S. P., and J. T. Grayston.
1991.
Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a.
J. Infect. Dis.
163:403-405[Medline].
|
| 28.
|
Yang, C. L.,
I. Maclean, and R. C. Brunham.
1993.
DNA sequence polymorphism of the Chlamydia trachomatis omp1 gene.
J. Infect. Dis.
168:1225-1230[Medline].
|
| 29.
|
Yuan, Y.,
Y.-X. Zhang,
N. G. Watkins, and H. D. Caldwell.
1989.
Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars.
Infect. Immun.
57:1040-1049[Abstract/Free Full Text].
|
| 30.
|
Zhang, Y.-X.,
S. Stewart,
T. Joseph,
H. R. Taylor, and H. D. Caldwell.
1987.
Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis.
J. Immunol.
138:575-581[Abstract].
|
| 31.
|
Zhang, Y.-X.,
S. G. Morrison, and H. D. Caldwell.
1990.
The nucleotide sequence of the major outer membrane protein gene of Chlamydia trachomatis serovar F.
Nucleic Acids Res.
18:1061[Free Full Text].
|
Journal of Clinical Microbiology, July 2001, p. 2655-2659, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2655-2659.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jalal, H., Stephen, H., Alexander, S., Carne, C., Sonnex, C.
(2007). Development of Real-Time PCR Assays for Genotyping of Chlamydia trachomatis. J. Clin. Microbiol.
45: 2649-2653
[Abstract]
[Full Text]
-
Xiong, L., Kong, F., Zhou, H., Gilbert, G. L.
(2006). Use of PCR and Reverse Line Blot Hybridization Assay for Rapid Simultaneous Detection and Serovar Identification of Chlamydia trachomatis. J. Clin. Microbiol.
44: 1413-1418
[Abstract]
[Full Text]